Wet AMD in its early stages can be treated with drugs to reduce the formation of new blood vessels, but this treatment is inefficient in cases where blood vessel formation is already in its advanced ...

According to reports, Belanger is a believer in Ocular mainly on the potential of its investigational Axpaxli, a drug that ...

Prospects for Novartis' ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3 trial in wet age-related macular degeneration (AMD).

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

New research shows that eating this tasty snack daily can help protect against the leading cause of vision loss in older ...

Ocular Therapeutix's Axpaxli targets wet AMD with long-acting treatment. Click here to find out why OCUL stock is a Strong ...

The United States Court of Appeals for the First Circuit recently joined the Sixth Circuit (2023) and Eighth Circuit (2022) ...

Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular ...

“Sozinibercept has the potential to become the first therapy in 20 years to improve visual outcomes in patients with wet AMD, ...

CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD -- Flexible Dosing and Extended Duration would be Important ...

Recognizing that wet AMD patients require individualized treatment ... axitinib behind the retina, thereby limiting drug exposure to the front of the eye. About Clearside’s Suprachoroidal ...